Abstract
Aberrant accumulation of beta-catenin in the cell nucleus as a result of deregulation of the Wnt/beta-catenin pathway is found in various types of cancer. Direct beta-catenin targeting agents are being researched despite obstacles; however, specific beta-catenin drugs for clinical treatments have not been approved so far. We focused on direct beta-catenin targeting of potential therapeutic value as anticancer agents. This review provides recent advances on small molecule beta-catenin agents. Structure-activity relationships and biological activities of reported inhibitors are discussed. This work provides useful knowledge in the discovery of beta-catenin agents.
Lingua originale | English |
---|---|
pagine (da-a) | 1-15 |
Numero di pagine | 15 |
Rivista | Molecules |
Volume | 27 |
DOI | |
Stato di pubblicazione | Pubblicato - 2022 |
Keywords
- anticancer agent
- inhibitor
- small molecule
- β-catenin